NCT00104078已完成1 期
Study Evaluating MYO-029 in Adult Muscular Dystrophy
Wyeth is now a wholly owned subsidiary of Pfizer9 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2005年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 108
- 试验地点
- 9
- 主要终点
- Safety assessment
研究概览
简要总结
The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD)
- •Independently ambulatory
排除标准
- •Patients with certain clinical conditions
- •Patients using steroids or other medications with the potential to affect muscle function
- •History of sensitivity to monoclonal antibodies or protein pharmaceuticals
- •Pregnant or lactating women.
结局指标
主要结局
Safety assessment
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)Myelodysplastic SyndromesNCT01822691H. Lee Moffitt Cancer Center and Research Institute15
招募中
1 期
Study of ATX-01 in Participants With DM1NCT06300307ARTHEx Biotech S.L.56
已完成
2 期
Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/FrailtySarcopeniaFrailtyAgingNCT05283486MyMD Pharmaceuticals, Inc.40
Unknown
1 期
The Efficacy of Using Far Infrared Radiation to Manage Muscular DystrophiesMuscular DystrophiesNCT00674843GAAD Medical Research Institute Inc.4
已完成
1 期
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy AdultsHealthy VolunteerBecker Muscular DystrophyNCT04585464Edgewise Therapeutics, Inc.127